Product Description
Matriks Biotek SHIKARI® Q-ATI (semi-quantitative)
Enzyme immunoassay for the semi-quantitative determination of total and free antibodies to infliximab in human serum and plasma.
Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. Free and Total Anti drug Antibody monitoring is highly importance along with measuring free drug from samples. Matriks Biotek Shikari Q-ATI semi-quantitative ELISA Kit measures Free and Total anti drug antibodies to Infliximab simultaneously on the same plate.
Total and Free (Semi-Quantitative) Specifications:
| Required Volume (µl) | 10 |
| Total Time (min) | 95 |
| Sample | Serum, Plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 15 |
| Spike Recovery (%) | - |
| Shelf Life (year) | 1 |
Documentation
Download IFU (Semi-Quantitative)
Download MSDS (Semi-Quantitative)
Please note that the documentation provided is for reference use only. For the most updated version, please contact us.
For Research Use Only
Manufactured by Matriks Biotek Co.
| Questions about this product? Ready to place an order? Email us at orders@iwai-chem.com or give us a call: (650) 486-1541 |
